Hyperion DeFi (HYPD) Stock Price, News & Analysis

Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Key Stats

• Today's Range: $3.48 to $3.82
• 50-Day Range: $2.82 to $4.67
• 52-Week Range: $1.07 to $17.18
• Volume: 597,445 shs
• Average Volume: 400,634 shs
• Market Capitalization: $44.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.88
• Consensus Rating: Hold

Hyperion DeFi Stock Analysis - MarketRank™

Hyperion DeFi scored higher than 58% of companies evaluated by MarketBeat, and ranked 348th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Hyperion DeFi has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

Hyperion DeFi has a consensus price target of $5.88, representing about 64.6% upside from its current price of $3.57.

Amount of Analyst Coverage

Hyperion DeFi has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -26.30%

Earnings Growth

Earnings for Hyperion DeFi are expected to decrease by -26.30% in the coming year, from $2.89 to $2.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hyperion DeFi is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hyperion DeFi is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hyperion DeFi has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.06% of the float of Hyperion DeFi has been sold short.

Short Interest Ratio / Days to Cover

Hyperion DeFi has a short interest ratio ("days to cover") of 3.74, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hyperion DeFi has recently decreased by 7.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hyperion DeFi does not currently pay a dividend.

Dividend Growth

Hyperion DeFi does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.40

News Sentiment

Hyperion DeFi has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Hyperion DeFi this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Hyperion DeFi to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hyperion DeFi insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.86% of the stock of Hyperion DeFi is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

25.84% of the stock of Hyperion DeFi is held by institutions.

Company Calendar

• Last Earnings: 3/26/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HYPD
• Previous Symbol: NASDAQ:EYEN
• CIK: 1682639
• Web: www.eyenovia.com
• Phone: (917) 289-1117
• Fax: N/A
• Employees: 40
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Hyperion DeFi: $5.88
• High Price Target: $7.75
• Low Price Target: $4.00
• Potential Upside/Downside: +62.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.25
• P/E Growth: N/A
• Net Income: -$45.31 million
• Net Margins: N/A
• Pretax Margin: -5,573.68%
• Return on Equity: -129.97%
• Return on Assets: -92.39%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 2.68
• Quick Ratio: 2.68

Sales & Book Value

• Annual Sales: $810 thousand
• Price / Sales: 54.55
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.73 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 12,220,000
• Free Float: 10,155,000
• Market Cap: $44.19 million
• Optionable: No Data
• Beta: 2.57